Question for written answer E-002410/2022/rev.1 to the Commission
Rule 138
Maria Arena (S&D), Anja Hazekamp (The Left), Eric Andrieu (S&D), Marie Toussaint (Verts/ALE), Martin Hojsík (Renew), Jutta Paulus (Verts/ALE), Cindy Franssen (PPE), Frédérique Ries (Renew), Tilly Metz (Verts/ALE)

Subject: Request for information on Draft Commission Implementing Act D080345 (SANTE/10146/2022)

On 30 March 2022, Parliament received Draft Commission Implementing Act D080345 extending the approval periods of a number of active substances owing to delays in their assessment, the reasons for which were beyond the control of the applicants, as well as in the ongoing assessment of the potential endocrine disrupting properties of some of those substances. Parliament has repeatedly expressed its discontent regarding extensions where there is substantiated concern as to the harmful properties of substances, on the grounds that they are not in line with the safety criteria laid down in Regulation (EC) No 1107/2009.

1. What are the reasons beyond the control of the applicants that led the Commission to extend the approval periods for these substances?

2. For each of the substances under assessment, what data are missing, what additional data have the applicants already been asked to provide, and what health and environmental concerns does the Commission expect to clarify with this additional data?

3. When is the Commission expecting to receive the data, will a comprehensive list of such data and the reason for requesting them be made publicly available, and by when will the assessments of each substance for which additional data have been requested be finalised?